Certificate of Analysis

Product Name: RECTAS

CAS Number: 101862-47-9 **IUPAC Name:** 2-Chloro-N-(2-furanylmethyl)-7H-purin-6-amine

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: Batch Molecular Weight: Physical Appearance: Solubility: Storage: **Batch Molecular Structure:** $C_{10}H_8CIN_5O.$ 249.66 Off White solid DMSO to 100 mM Store at -20°C

2. ANALYTICAL DATA


HPLC: ¹H NMR: Mass Spectrum: **Microanalysis:**

Shows 97.6% purity Consistent with structure Consistent with structure

Carbon Hydrogen Nitrogen Theoretical 48.11 28.05 3.23 Found 47.91 3.21 28.32

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com **North America** China **Europe Middle East Africa Rest of World** info@bio-techne.com Tel: (800) 343 7475 info.cn@bio-techne.com Tel: +44 (0)1235 529449 www.tocris.com/distributors Tel: +86 (21) 52380373 techsupport@bio-techne.com Tel:+1 612 379 2956



www.tocris.com

Print Date: Jun 13th 2022

Catalog No.: 7679 Batch No.: 1

DC R biotechne

Print Date: Jun 13th 2022

www.tocris.com

RECTAS Product Name:

CAS Number: 101862-47-9 **IUPAC Name:** 2-Chloro-N-(2-furanylmethyl)-7H-purin-6-amine

Description:


RECTAS (rectifier of aberrant splicing) is a pre-mRNA splicing modulator of the IKBKAP (inhibitor of k light polypeptide gene enhancer in B-cells, kinase complex associated protein) gene. It corrects aberrant IKBKAP splicing in vitro in cellular models of familial dysautonomia and in vivo in transgenic mice. In combination with Phenylbutyric acid (Cat. No. 2682), RECTAS rescues PARK7 aberrant splicing and neuronal cell loss in a midbrain organoid model of familial Parkinson's disease. Orally bioavailable and brain penetrant.

Physical and Chemical Properties:

Batch Molecular Formula: C₁₀H₈ClN₅O. Batch Molecular Weight: 249.66 Physical Appearance: Off White solid

Minimum Purity: ≥98%

Batch Molecular Structure:



References:

Ajiro et al (2021) Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia. Nat.Commun. 12 4507. PMID: 34301951 .

Boussaad et al (2020) A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson's disease. Sci. Transl. Med. 12 eaau3960. PMID: 32908004.

Yoshida et al (2015) Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia. Proc.Natl.Acad.Sci U.S.A. 112 2764. PMID: 25675486.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com	North America	China	Europe Middle East Africa	Rest of World
info@bio-techne.com techsupport@bio-techne.com	Tel: (800) 343 7475	info.cn@bio-techne.com Tel: +86 (21) 52380373	Tel: +44 (0)1235 529449	www.tocris.com/distributors Tel:+1 612 379 2956

Storage: Store at -20°C

Solubility & Usage Info: DMSO to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Catalog No.: 7679

Batch No.: 1